MedTrace Logo

Comparison of Platelet Inhibition With Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel According to Hepatic Cytochrome 2C19 Allele (CYP2C19) Polymorphism

NCT00891670 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2009-05-01

No results posted yet for this study

Summary

The purpose of this study was to determine the impact of adjunctive cilostazol on platelet inhibition in carriers and non-carriers of the loss-of-function CYP2C19 allele.

Conditions

  • Coronary Artery Stenosis
  • Maximal Platelet Aggregation
  • Late Platelet Aggregation
  • High Post-Treatment Platelet Reactivity

Interventions

DRUG

cilostazol

100mg twice daily for at least 1 month

DRUG

clopidogrel

75mg once daily (triple group arm) 150mg once daily (high maintenance dose group arm)

DRUG

aspirin

aspirin 100mg

Sponsors & Collaborators

  • Gyeongsang National University Hospital

    lead OTHER

Principal Investigators

  • Young-Hoon Jeong, MD, phD · Gyeong-Sang Natinal University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2009-06-30
Completion
2009-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00891670 on ClinicalTrials.gov